Work

Nipocalimab‐aahu (IMAAVY) for Generalized Myasthenia Gravis: Redefining Treatment With FcRn Inhibition

Year: 2025

Type: article

Abstract: FDA approval of IMAAVY (nipocalimab) marks a major advancement in the management of generalized myasthenia gravis (gMG). Clinical trial data showed significant improvements in MG-ADL scores, especially in AChR-positive patients, while also highlighting its favorable safety profile, potential for subcutaneous self-administration, and greater affordability compared with existing therapies.

Source: Medicine Advances

DOI: 10.1002/med4.70043

Authors: Muhammad Affan Abid, Malaika Manzoor, Reham Jamal, Humaiz Ahmed

Institutions: Dow University of Health Sciences, Karachi Medical and Dental College

Language: English

Topic: Myasthenia Gravis and Thymoma

Subfield: Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W4417289123

FWCI:

Cites: 7

Cited by:

Related to: